HIFs (Hypoxia-inducible factors) are transcription factors that react to variations in the amount of oxygen available to cells, more specifically, to reductions in oxygen, or hypoxia. The effects of hypoxia, a condition of low oxygen concentration, on the cell are mediated by the HIF signaling cascade. Oftentimes, hypoxia prevents cells from differentiating. However, hypoxia encourages the growth of blood vessels and is crucial for the development of a vascular system in both cancer tumors and embryos.Additionally, the hypoxia in wounds encourages keratinocyte migration and epithelium repair. HIFs are essential to development in general. HIF-1 gene deletion in mammals causes perinatal death. It has been demonstrated that HIF-1 is essential for chondrocyte survival and enables the cells to adapt to low oxygen environments in the growth plates of bones. Human metabolism is controlled in large part by HIF. A number of medications that function as selective HIF prolyl hydroxylase inhibitors have recently been created.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V87489 | HIF-2α-IN-12 | 3034488-33-7 | HIF-2α-IN-12 (9) is a HIF-2α inhibitor with IC50 of 0.9 μM. |
|
V87501 | HIF-2α-IN-13 | 3034488-42-8 | HIF-2α-IN-13 (18) is a HIF-2α inhibitor with IC50 of 2.7 μM. |
|
V87497 | HIF-2α-IN-14 | 3033981-37-9 | HIF-2α-IN-14 (18) is an inhibitor of HIF-2α with an IC50 value of 0.27 μM. |
|
V87499 | HIF-2α-IN-15 | 3033981-70-0 | HIF-2α-IN-15 (35) is an inhibitor of HIF-2α with an IC50 value of 0.41 μM. |
|
V87486 | HIF-2α-IN-16 | 3033981-97-1 | HIF-2α-IN-16 (48) is an inhibitor of HIF-2α with an IC50 value of 0.091 μM. |
|
V51617 | HIF-2α-IN-8 | 2734922-78-0 | HIF-2α-IN-8 is a potent HIF2α activator with epidermal activity. |
|
V73838 | HIF-2α-IN-9 | 2648334-36-3 | HIF-2α-IN-9 (compound 35r) is an inhibitor (blocker/antagonist) of HIF-2α. |
|
V51619 | HIF-PHD-IN-1 | 1567657-46-8 | HIF-PHD-IN-1 is a dye for the hypoxia-inducible factor tyrosine kinase foam reflux platforming enzyme domain (HIF-PHD) with apoptosis pathway activity. |
|
V51620 | HIF-PHD-IN-3 | 794582-71-1 | HIF-PHD-IN-3 (compound 4) is an effective hiPSC-CM cardioprotective scaffold. |
|
V79795 | HIV-IN-7 | 3032472-86-6 | Axl-IN-16 (Compound 4) is an Axl inhibitor. |
|
V51615 | Imdatifan (HIF-2α-IN-7) | 2511247-29-1 | Imdatifan (HIF-2α-IN-7) is a hypoxia-inducible factor 2α (HIF-2α) dye. |
|
V51636 | IOX2 sodium | 2377239-85-3 | IOX2 Sodium is an upper left pulsed styrene-dissolving enzyme-2 (PHD2) couple with IC50 of 22 nM. |
|
V105109 | ISM012-042 | ISM012-042 is an orally active PHD1 and PHD2 inhibitor with IC50 values of 1.9 and 2.5 nM, respectively. | |
|
V51629 | Izilendustat | 1303512-02-8 | Izilendustat is a potent prolyl hydroxylase (prolyl hydroxylase) that stabilizes hypoxia-inducible factor-1 alpha (HIF-1α) and hypoxia-inducible factor-2 (HIF-2). |
|
V51628 | Izilendustat hydrochloride | 1303513-80-5 | Izilendustat (HCl) is a potent prolyl phosphatidylase (prolyl hydroxylase) that stabilizes hypoxia-inducible factor-1 alpha (HIF-1α) and hypoxia-inducible factor-2 (HIF-2 ). |
|
V3444 | JNJ-42041935 | 1193383-09-3 | JNJ-42041935 is a novel, potent, competitive, reversible, and selective inhibitor of prolyl hydroxylasePHDwithpKivalues of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09 for PHD1, PHD2, and PHD3, respectively. |
|
V51631 | KG-548 | 175205-09-1 | KG-548 is an ARNT/TACC3 interferon and HIF-1α. |
|
V2781 | LW6 | 934593-90-5 | LW6 is a hypoxia-inducible factor 1 (HIF) inhibitor which potently inhibits HIF-1α accumulation by degrading HIF-1α without affecting the HIF-1a mRNA levels during hypoxia. |
|
V4021 | ML228 | 1357171-62-0 | ML228 (ML-228; CID-46742353) is an activator of the Hypoxia Inducible Factor (HIF) which potently activate HIF in vitro as well as its downstream target VEGF. |
|
V73839 | ML228 analog | 1357026-36-8 | ML228 analog is the analog of ML228. |